Do analysts rate AIMD or HYFT?

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 222.58%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable earnings & valuation, AIMD or HYFT?

Ainos has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 127.80 -$14.77M -$2.89 N/A MindWalk $17.59M 4.07 -$21.69M -$0.20 N/A

Is AIMD or HYFT more profitable?

MindWalk has a net margin of -66.79% compared to Ainos' net margin of -11,912.10%. MindWalk's return on equity of -69.37% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% MindWalk -66.79% -69.37% -39.74%

Do analysts prefer CING or AIMD?

Cingulate presently has a consensus target price of $27.33, suggesting a potential upside of 468.26%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cingulate is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CING or AIMD?

Ainos has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A Ainos $120K 127.80 -$14.77M -$2.89 N/A

Is CING or AIMD more profitable?

Cingulate has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Ainos -11,912.10% -160.55% -62.29%

Do analysts rate BHST or AIMD?

BioHarvest Sciences currently has a consensus price target of $10.00, suggesting a potential upside of 243.64%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe BioHarvest Sciences is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BHST or AIMD more profitable?

BioHarvest Sciences has a net margin of -32.54% compared to Ainos' net margin of -11,912.10%. BioHarvest Sciences' return on equity of -76.03% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets BioHarvest Sciences -32.54% -76.03% -25.30% Ainos -11,912.10% -160.55% -62.29%

Do analysts recommend ACRV or AIMD?

Acrivon Therapeutics currently has a consensus price target of $11.67, indicating a potential upside of 620.16%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACRV or AIMD more profitable?

Acrivon Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Acrivon Therapeutics' return on equity of -64.43% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Ainos -11,912.10% -160.55% -62.29%

Do analysts prefer UPXI or AIMD?

Upexi currently has a consensus price target of $8.33, indicating a potential upside of 954.85%. Given Upexi's stronger consensus rating and higher probable upside, research analysts plainly believe Upexi is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, UPXI or AIMD?

Upexi has higher revenue and earnings than Ainos. Upexi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $15.81M 3.51 -$13.68M -$0.62 N/A Ainos $120K 127.80 -$14.77M -$2.89 N/A

Is UPXI or AIMD more profitable?

Upexi has a net margin of -874.00% compared to Ainos' net margin of -11,912.10%. Upexi's return on equity of -66.70% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Ainos -11,912.10% -160.55% -62.29%

Ainos (AIMD) Competitors

$1.80 -0.05 (-2.70%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.01 (+0.56%)

As of 06/24/2026 07:46 PM Eastern

Compare

AIMD vs. HYFT, CING, BHST, ACRV, and UPXI

Should you buy Ainos stock or one of its competitors? MarketBeat compares Ainos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ainos include MindWalk (HYFT), Cingulate (CING), BioHarvest Sciences (BHST), Acrivon Therapeutics (ACRV), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

How does Ainos compare to MindWalk?

Ainos (NASDAQ:AIMD) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Ainos' average media sentiment score of 0.00 equaled MindWalk'saverage media sentiment score.

Company	Overall Sentiment
Ainos	Neutral
MindWalk	Neutral

Ainos has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

6.7% of MindWalk shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ainos has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	127.80	-$14.77M	-$2.89	N/A
MindWalk	$17.59M	4.07	-$21.69M	-$0.20	N/A

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 222.58%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

MindWalk has a net margin of -66.79% compared to Ainos' net margin of -11,912.10%. MindWalk's return on equity of -69.37% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
MindWalk	-66.79%	-69.37%	-39.74%

Summary

MindWalk beats Ainos on 10 of the 15 factors compared between the two stocks.

How does Ainos compare to Cingulate?

Cingulate (NASDAQ:CING) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

In the previous week, Cingulate had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Ainos. Cingulate's average media sentiment score of 0.84 beat Ainos' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
Ainos	Neutral

Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Ainos has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

41.3% of Cingulate shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cingulate presently has a consensus target price of $27.33, suggesting a potential upside of 468.26%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cingulate is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cingulate has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Ainos	-11,912.10%	-160.55%	-62.29%

Ainos has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Ainos	$120K	127.80	-$14.77M	-$2.89	N/A

Summary

Ainos beats Cingulate on 8 of the 15 factors compared between the two stocks.

How does Ainos compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

BioHarvest Sciences has a net margin of -32.54% compared to Ainos' net margin of -11,912.10%. BioHarvest Sciences' return on equity of -76.03% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Ainos	-11,912.10%	-160.55%	-62.29%

BioHarvest Sciences has higher revenue and earnings than Ainos. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	1.65	-$11.14M	-$0.59	N/A
Ainos	$120K	127.80	-$14.77M	-$2.89	N/A

BioHarvest Sciences currently has a consensus price target of $10.00, suggesting a potential upside of 243.64%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe BioHarvest Sciences is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioHarvest Sciences had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for Ainos. BioHarvest Sciences' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Ainos	Neutral

BioHarvest Sciences has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Ainos has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market.

Summary

BioHarvest Sciences beats Ainos on 10 of the 13 factors compared between the two stocks.

How does Ainos compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Acrivon Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Ainos has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market.

Acrivon Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Acrivon Therapeutics' return on equity of -64.43% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Ainos	-11,912.10%	-160.55%	-62.29%

Ainos has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Ainos	$120K	127.80	-$14.77M	-$2.89	N/A

In the previous week, Acrivon Therapeutics' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
Ainos	Neutral

Acrivon Therapeutics currently has a consensus price target of $11.67, indicating a potential upside of 620.16%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Ainos on 9 of the 13 factors compared between the two stocks.

How does Ainos compare to Upexi?

Upexi (NASDAQ:UPXI) and Ainos (NASDAQ:AIMD) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Upexi has a net margin of -874.00% compared to Ainos' net margin of -11,912.10%. Upexi's return on equity of -66.70% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Ainos	-11,912.10%	-160.55%	-62.29%

Upexi has higher revenue and earnings than Ainos. Upexi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	3.51	-$13.68M	-$0.62	N/A
Ainos	$120K	127.80	-$14.77M	-$2.89	N/A

Upexi has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market. Comparatively, Ainos has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market.

5.7% of Upexi shares are held by institutional investors. 9.0% of Upexi shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Upexi had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Upexi and 0 mentions for Ainos. Upexi's average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company	Overall Sentiment
Upexi	Neutral
Ainos	Neutral

Upexi currently has a consensus price target of $8.33, indicating a potential upside of 954.85%. Given Upexi's stronger consensus rating and higher probable upside, research analysts plainly believe Upexi is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Upexi beats Ainos on 12 of the 16 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIMD vs. The Competition

Export

Metric	Ainos	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.77M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-0.62	18.65	25.37	23.95
Price / Sales	127.80	341.96	530.17	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	1.40	4.14	10.76	6.41
Net Income	-$14.77M	$64.45M	$3.56B	$337.14M
7 Day Performance	-4.41%	1.22%	0.99%	-1.06%
1 Month Performance	17.65%	0.95%	0.79%	0.49%
1 Year Performance	-29.06%	25.22%	30.25%	28.43%

Ainos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIMD Ainos	0.6612 of 5 stars	$1.80 -2.7%	N/A	-27.7%	$15.77M	$120K	N/A	40
HYFT MindWalk	2.037 of 5 stars	$1.53 +2.0%	$5.00 +226.8%	N/A	$71.32M	$17.59M	N/A	80	Gap Up
CING Cingulate	3.2858 of 5 stars	$5.23 +2.1%	$27.33 +422.6%	+17.9%	$69.72M	N/A	N/A	20
BHST BioHarvest Sciences	2.3614 of 5 stars	$3.43 +4.5%	$10.00 +191.6%	-57.8%	$67.24M	$35.16M	N/A	N/A
ACRV Acrivon Therapeutics	1.7424 of 5 stars	$1.55 +1.6%	$11.67 +655.1%	+30.6%	$66.13M	N/A	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIMD) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ainos (AIMD) Competitors